Axsome Therapeutics appoints Dr. Susan Mahony to board of directors

Axsome Therapeutics, Inc.

Board expanded from 4 to 5 directors; Dr. Mahony appointed effective Oct. 10, 2023.
Former Horizon Therapeutics board member and ex-SVP/President of Lilly Oncology.
Received initial option grant worth $325,000 vesting over 3 years and a pro-rated grant of $81,250 vesting in 1 year.
Annual cash retainer for non-employee directors, pro-rated for 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Susan Mahony

Director

AXSM · Axsome Therapeutics, Inc.

Effective: 2023-10-10
Filed: October 11, 2023, 7:59 PM ET

The Board of Directors (the “Board”) of Axsome Therapeutics, Inc. (the “Company”), increased the size of the Board from four to five directors, and on October 8, 2023 appointed Dr. Susan Mahony as a director to be effective as of October 10, 2023 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Susan Mahony was appointed as Director at Axsome Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board of Directors (the “Board”) of Axsome Therapeutics, Inc. (the “Company”), increased the size of the Board from four to five directors, and on October 8, 2023 appointed Dr. Susan Mahony as a director to be effective as of October 10, 2023 (the “Effective Date”).

View on SEC.gov

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-052940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.